Spectral Diagnostics, Inc.
Spectral Diagnostics, Inc. engages in the development and commercialization of the theranostic treatment for severe sepsis and septic shock. The company's products include Endotoxin Activity Assay and Toraymyxin. The Endotoxin Activity Assay identifies patients at risk of developing sepsis and certain proprietary biological reagents. The Toraymyxin acts as Polymyxin B extracorporeal direct hemoperfusion device that removes circulating endotoxin from the bloodstream. It operates through two subsidiaries: Spectral Diagnostics (U.S.), Inc. and Spectral Diagnostics (New Brunswick), Inc. Spectral Diagnostics was founded on July 29, 1991 and is headquartered in Toronto, Canada.